Skip to main content

Hikal Limited (HIKAL.BO)

Bombay Stock Exchange (India) Healthcare Drug Manufacturers - Specialty & GenericView data quality →
52.2Fair

ValueMarkers Composite Index

Top 39%#27,488 of 44,707
Overvalued

95% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
5.00
High Risk
Altman
3.43
Safe
DCF Value
$1
Overvalued
ROIC
8.8%
Adequate
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Hikal Limited (HIKAL.BO) — VMCI valuation read

HIKAL.BO prints VMCI 52/100 inside the Healthcare sector, where the median sits at 50. The 2-point above-median delta is the cleanest single-number summary of Hikal Limited's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On HIKAL.BO, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** HIKAL.BO trades at 14.0x earnings, 22% below the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -0.6x leaves covenant headroom; that is the risk line for Hikal Limited on the trailing financials.

HIKAL.BO rose 1.5% over the trailing 7 days, with a -23.6% read on a 30-day basis.

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

CEO: Jai Vishwanath Hiremath2,061 employeesINwww.hikal.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in HIKAL.BO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.